[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Mỹ Đức Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":440},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,52,78,102,124,158,186,215,241,263,285,312,342,366,393,416],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100644889","endometrial-peristalsis-and-pregnancy-outcomes-in-hormone-replacement-therapy-hrt---frozen-embryo-transfer-fet-cycles-100644889",false,"NCT07675213","Endometrial Peristalsis and Pregnancy Outcomes in Hormone Replacement Therapy (HRT) - Frozen Embryo Transfer (FET) Cycles","Correlation Between Endometrial Peristalsis And Pregnancy Outcomes In Patients Undergoing Frozen Embryo Transfer With Hormone Replacement Therapy for Endometrial Preparation Protocol","CONCO","Inclusion Criteria:\n\n* Women aged 18 - 42 years old\n* Scheduled for frozen embryo transfer cycles using hormone replacement therapy protocol\n* Transferred no more than two cleavage embryos or one good-quality blastocyst or no more than two poor-quality blastocysts\n* Provision of written informed consent to participate\n\nExclusion Criteria:\n\n* Having an allergy and contraindications for exogenous hormone administration (e.g., breast cancer, thromboembolic disease)\n* Cycles with preimplantation genetic testing, oocyte donation, or in vitro maturation\n* Having untreated uterine or adnexal abnormalities (e.g., intrauterine adhesions, unicornuate\u002F bicornuate\u002F arcuate uterus, endometrial polyp, large leiomyoma ≥5 cm in diameter, hydrosalpinx, endometrial hyperplasia)\n* Use of uterine relaxants or intralipid infusion during the embryo transfer process\n* Use of a GnRH-agonist for downregulation within one month","FEMALE","18 Years","42 Years",{"count":21,"type":22},442,"ESTIMATED","OBSERVATIONAL","Endometrial peristalsis may influence embryo implantation and pregnancy outcomes, but its role during hormone replacement therapy (HRT)-prepared frozen embryo transfer (FET) cycles remains unclear. This prospective observational study will assess endometrial peristalsis at predefined time points during HRT-prepared FET cycles using transvaginal ultrasonography and evaluate its association with pregnancy outcomes. The study aims to clarify the clinical significance of endometrial peristalsis in HRT-prepared FET cycles and to provide evidence supporting endometrial assessment in assisted reproductive technology.",[26,27,28,29,30,31,32],"Infertility","Endometrial Peristalsis","Uterine Contraction","Endometrial Waves","Frozen Embryo Transfer (FET)","Uterine Peristalsis","Hormone Replacement Therapy (HRT)",[34,35,36,37,38],"endometrial peristalsis","uterine contractions","endometrial waves","frozen embryo transfer","artificial cycles","NOT_YET_RECRUITING","2026-06-29",{"date":42,"type":43},"2026-07-01","ACTUAL",{"date":45,"type":22},"2026-06-30",{"date":47,"type":22},"2027-12-01",{"name":49,"class":50},"Mỹ Đức Hospital","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":51},"100534480","artificial-cycle-with-or-without-gnrh-agonist-pre-treatment-for-frozen-embryo-transfer-in-adenomyosis-patients-100534480","NCT06239376","Artificial Cycle With or Without GnRH Agonist Pre-treatment for Frozen Embryo Transfer in Adenomyosis Patients","The Effectiveness of the Two Different Endometrial Preparation Regimes for Frozen Embryo Transfer in Patients With Adenomyosis","FET-ADE","Inclusion Criteria:\n\n* Confirm diagnosis with adenomyosis by using transvaginal ultrasonography (MUSA consensus) and\u002For pelvic magnetic resonance imaging.\n* Age between 18 - 42\n* Undergo less or equal to three previous IVF cycles\n* Indicate for frozen embryo transfer\n* Agree to have not more than two day-3 embryo or one blastocyst (day-5 and day-6) transferred\n* Not participating in any other study\n\nExclusion Criteria:\n\n* Embryos from IVM cycle\n* Having uterine or adnexal abnormalities (e.g., intrauterine adhesions, unicornuate\u002F bicornuate\u002F arcuate uterus; unremoved hydrosalpinx, endometrial polyp, submucosal leiomyoma, or leiomyoma with endometrial cavity distortion)\n* Having contraindications for exogenous hormones administration: breast cancer, risks of venous thromboembolism\n* Embryos from the oocyte donation cycle.\n* Patients with a history of GnRH injection within three months, measured from the last GnRHa injection to the study screening date.",{"count":61,"type":22},222,"INTERVENTIONAL",[64],"NA","This randomized clinical trial aims to assess the comparative effectiveness of two distinct endometrial preparation protocols for frozen embryo transfer (FET) among women with adenomyosis undergoing IVF\u002FICSI. Specifically, it seeks to address the following key questions:\n\n1. Does the protocol involving the combination of GnRH agonist and letrozole for down regulation with exogenous steroids (GnRHa+AI - AC) result in a higher live birth rate compared to the use of exogenous steroids alone (AC) in women with adenomyosis undergoing frozen embryo transfer?\n2. What are the common side effects of the GnRHa+AI - AC regimen?\n\nEligible participants will undergo screening before endometrial preparation for FET, following which they will be randomly assigned to one of two groups: GnRHa+AI - AC or AC. In the GnRHa+AI - AC group, participants will be pre-treated with GnRH agonist and letrozole two months before endometrial preparation. After this period, participants will return for endometrial preparation, and any side effects resulting from the down regulation will be evaluated. In contrast, the AC group will receive standard treatment.",[67,68,69],"Adenomyosis","IVF","Frozen Embryo Transfer","RECRUITING","2026-06-27",{"date":42,"type":43},{"date":74,"type":43},"2024-02-19",{"date":76,"type":22},"2027-05-30",{"name":49,"class":50},{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":62,"phases":89,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":51},"100641929","apply-biphasic-ivm-for-poseidon-group-1-100641929","NCT07632300","Apply Biphasic IVM for POSEIDON Group 1","Efficacy and Safety of Biphasic IVM in Low Prognosis Patients Classified as Poseidon Group 1A","POSEIDON-Ia","Inclusion Criteria:\n\n* Women aged 18 - \\\u003C 35 years\n* At least one IVF cycle have been failed and classified as having a poor response to POSEIDON group Ia.\n* POSEIDON group Ia ( \\\u003C 35 age; AMH \\>= 1.2 ng\u002Fml and\u002For AFC \\>=5 antral follicles; have \\\u003C 4 oocytes was retrieved at previous IVF cycle)\n* Agree to apply biphasic-IVM treatment.\n* Agree to freeze all embryos and to transfer the frozen embryos afterward.\n* Agree to participate in the study.\n\nExclusion Criteria:\n\n* Egg-donation cycle\n* Uterine abnormalities: adenomyosis, large uterine fibroids (≥5 cm), bicornuate uterus, uterine adhesions.\n* Sperm surgical (PESA, TESE, mTESE)\n* PGT","35 Years",{"count":88,"type":22},25,[64],"The goal of this clinical trial is to learn if biphasic In Vitro Maturation (IVM) works to help young women who produce very few oocytes after controlled ovarian stimulation. The study focuses on women under age 35 who have a good number of follicles in their ovaries but do not respond well to standard ovarian stimulation by Gonadotropin (known as POSEIDON Group 1a).\n\nThe main questions it aims to answer are:\n\nHow many mature oocytes can be obtain after biphasic -VM? Researchers will use biphasic-IVM system to see if it can bypass the problems these patients face with standard treatments, such as high costs and the risk of medical complications like Ovarian Hyperstimulation Syndrome (OHSS).\n\nParticipants will:\n\nHave their immature eggs collected from the ovaries without the need for high-dose hormone injections.\n\nHave their eggs matured in a specialized laboratory using a two-step process (biphasic IVM) to improve egg quality.\n\nFollow up with researchers to check the number of embryos created and the safety of the procedure.",[92,93],"Healthy Adult Females","Healthy Adult Male","2026-06-15",{"date":96,"type":43},"2026-06-17",{"date":98,"type":43},"2026-06-12",{"date":100,"type":22},"2027-03-30",{"name":49,"class":50},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":110,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":112,"conditions":113,"keywords":114,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":122,"locationsCount":123},"100620503","impact-of-fet-preparation-protocol-on-endometrial-peristalsis-a-prospective-cohort-study-100620503","NCT07358468","Impact Of FET Preparation Protocol On Endometrial Peristalsis: A Prospective Cohort Study","Effects Of Endometrial Preparation Protocols On Peristalsis And Pregnancy Rates In Frozen Embryo Transfer: A Prospective Cohort Study","EPFE","Inclusion Criteria:\n\n* Women aged 18 - 42 years old\n* Scheduled for frozen embryo transfer cycles using hormone replacement therapy protocol or natural cycle protocol (True natural cycles or modified natural cycles)\n* Transferred no more than two cleavage embryos or one good-quality blastocyst or no more than two poor-quality blastocysts\n\nExclusion Criteria:\n\n* Having an allergy and contraindications for exogenous hormone administration (e.g., breast cancer, thromboembolic disease)\n* Cycles with preimplantation genetic testing, oocyte donation, or in vitro maturation\n* Having untreated uterine or adnexal abnormalities (e.g., intrauterine adhesions, unicornuate\u002F bicornuate\u002F arcuate uterus, endometrial polyp, large leiomyoma ≥5 cm in diameter, hydrosalpinx, endometrial hyperplasia).\n* Use of uterine relaxants or intralipid infusion during the embryo transfer process.\n* Use of a GnRH-agonist for downregulation within one month.\n* PCOS patients",{"count":111,"type":22},356,"The uterus is a dynamic muscular organ that undergoes rhythmic, wave-like contractions known as endometrial peristalsis or endometrial waves. This muscular activity, which is an essential component of natural fertility, presents a nuanced and sometimes contradictory role in the context of assisted reproductive treatments. Endometrial peristalsis refers to the frequency, amplitude, and pattern of myometrial contractions occurring in different reproductive phases. These peristalsis play vital roles in sperm transport, embryo migration, and implantation. Clinical and imaging studies suggest that abnormal patterns or excessive contractility at the time of embryo transfer may disrupt endometrial-embryo synchrony, impair implantation, and increase miscarriage risk. However, most evidence on endometrial peristalsis pertains to fresh embryo transfer cycles, natural conceptions, or pathological contexts, such as adenomyosis or fibroids, with limited insights regarding its effects on different endometrial preparation protocols in frozen embryo transfer (FET). Understanding the dynamics of endometrial peristalsis in this context is clinically important, as inappropriate contractile activity could physically expel the embryo or create a non-receptive environment, ultimately reducing the chances of live birth. Despite its theoretical significance, there is a paucity of robust, prospective data correlating endometrial peristalsis patterns measured around the time of FET with different endometrial preparation protocols with subsequent pregnancy outcomes.",[26,27,28,29,30,31],[34,35,36,37,115,38],"natural cycles","2026-03-17",{"date":118,"type":43},"2026-03-18",{"date":120,"type":43},"2026-02-22",{"date":47,"type":22},{"name":49,"class":50},2,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":135,"conditions":136,"keywords":141,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":123},"100612720","levothyroxine-treatment-and-ivf-outcomes-in-women-with-subclinical-hypothyroidism-a-target-trial-emulation-100612720","NCT07257250","Levothyroxine Treatment and IVF Outcomes in Women With Subclinical Hypothyroidism: A Target Trial Emulation","Effectiveness of Levothyroxine Treatment on In Vitro Fertilization and Pregnancy Outcome in Women With Subclinical Hypothyroidism and Infertility: A Target Trial Emulation","LESI","Inclusion Criteria:\n\n* Women aged 18-45 years.\n* Diagnosed with subclinical hypothyroidism (TSH 4.2-\\\u003C10 mIU\u002FL with FT4 0.92-1.68 ng\u002FdL).\n* Undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) followed by frozen embryo transfer (FET).\n\nExclusion Criteria:\n\n* Overt hypothyroidism (TSH ≥10 mIU\u002FL and FT4 ≤0.92 ng\u002FdL).\n* Current or recent (within 1 month) use of drugs affecting thyroid function (levothyroxine, amiodarone, methimazole, propylthiouracil).","45 Years",{"count":134,"type":22},900,"Subclinical hypothyroidism (SCH) is defined by elevated thyroid-stimulating hormone (TSH) with normal free thyroxine (fT4) levels. It affects approximately 5-7% of women of reproductive age and may negatively influence outcomes of assisted reproductive technology (ART). During controlled ovarian stimulation, rising estradiol increases thyroxine-binding globulin and thyroid hormone requirements. These physiological changes, combined with increased metabolic demand in early pregnancy, may worsen SCH and contribute to adverse outcomes such as miscarriage, preterm birth, and hypertensive disorders of pregnancy.\n\nAlthough levothyroxine (LT4) is routinely used to treat overt hypothyroidism, evidence for its benefit in SCH, especially among infertile women undergoing In Vitro Fertilization (IVF) or Intra-Cytoplasmic Sperm Injection (ICSI) with frozen embryo transfer (FET), remains inconclusive. Some trials and meta-analyses have shown reductions in miscarriage and neonatal mortality, while others have found no improvement in ART or obstetric outcomes.\n\nThis study aims to evaluate the effectiveness of levothyroxine therapy on IVF\u002FFET outcomes and subsequent pregnancy results in women with subclinical hypothyroidism and infertility. This retrospective cohort study will emulate the target trial to evaluate whether LT4 treatment, titrated to achieve a pre-transfer TSH \\\u003C 2.5 mIU\u002FL, improves implantation, live birth, and obstetric outcomes compared with expectant management.",[137,26,138,139,140,30],"Subclinical Hypothyroidism","Assisted Reproductive Technology","In Vitro Fertilization (IVF)","Intracytoplasmic Sperm Injection",[142,137,26,143,68,144,69,145,138,146,147,148,149],"Levothyroxine","Thyroid Disorders","ICSI","FET","Live Birth","Miscarriage","Pregnancy Outcomes","Thyroid Autoimmunity","2026-01-13",{"date":152,"type":43},"2026-01-14",{"date":154,"type":43},"2019-01-01",{"date":156,"type":22},"2026-03-30",{"name":49,"class":50},{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":168,"conditions":169,"keywords":174,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":185,"locationsCount":51},"100608107","transcriptomic-profiling-of-cumulus-cells-from-capa-ivm-100608107","NCT07197255","Transcriptomic Profiling of Cumulus Cells From CAPA-IVM","Transcriptomic Profiling of Cumulus Cells From CAPA-IVM Cycles in Women With PCOS: A Prospective Pilot Study","Inclusion Criteria:\n\n* Women 18-38 years\n* BMI =\\\u003C 32kg\u002Fm2\n* Diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam 2003 criteria, meet at least 2 of the following 3 features: (1) Oligo-ovulation or anovulation. (2) Clinical and\u002For biochemical signs of hyperandrogenism (3) Polycystic ovarian morphology on ultrasound.\n* Indicated for CAPA-IVM treatment.\n* Serum AMH ≥ 4 ng\u002FmL (28.57 pmol\u002FL).\n* Antral follicle count (AFC) ≥ 24 follicles in both ovaries at the time of CAPA-IVM indication.\n* Signed informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Retrieved sperm from surgical procedures\n* Previous IVF cycle with total immature oocytes","38 Years",{"count":167,"type":22},10,"Capacitation in vitro maturation (CAPA-IVM) has improved oocyte maturation and resulted in live births. Because cumulus cells (CCs) communicate bidirectionally with the oocyte, their transcriptomic profile may serve as a non-invasive biomarker of oocyte and embryo competence. This prospective pilot study will analyze CCs gene expression after CAPA-IVM using RNA sequencing and pathway analysis, and correlate findings with embryological outcomes including fertilization, day-3 cleavage, and blastocyst formation. Results are expected to provide insights into the molecular basis of oocyte competence and support development of non-invasive embryo selection strategies.",[170,171,172,173],"PCOS (Polycystic Ovary Syndrome)","Cumulus Cell","Capacitation IVM","Transcriptomic Profiling",[175,176,177,178],"In vitro maturation","CAPA-IVM","Cumulus cells","Transcriptomics","2025-11-20",{"date":181,"type":43},"2025-11-21",{"date":183,"type":43},"2025-10-16",{"date":156,"type":22},{"name":49,"class":50},{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":194,"targetDuration":4,"studyType":62,"phases":196,"briefSummary":197,"conditions":198,"keywords":202,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":51},"100606162","ivm---fresh-et-the-saigon-protocol-versus-ivf---fet-in-pcos-women-100606162","NCT07171970","IVM - Fresh ET (THE SAIGON PROTOCOL) Versus IVF - FET in PCOS Women","The Effectiveness and Safety of In Vitro Maturation With Fresh Embryo Transfer (The SAIGON Protocol) Versus In Vitro Fertilization With Frozen Embryo Transfer in Women With Polycystic Ovary Syndrome","SAIGON-PTC","Inclusion Criteria:\n\n* Women aged 18 - 42 years old.\n* Diagnosed with PCOS, followed Rotterdam 2003 criteria (Group TREP consensus workshop, 2004)\n* Had fewer than three previous failed frozen embryo transfer (FET) cycles\n* Transferred no more than two cleavage embryos or one good-quality blastocyst or no more than two poor-quality blastocysts.\n* Agreeing to participate in the study\n\nExclusion Criteria:\n\n* Having allergy and contraindications for exogenous hormone administration (e.g., breast cancer, thromboembolic disease)\n* Cycles with preimplantation genetic testing indication\n* Oocyte donation cycles\n* Having untreated uterine or adnexal abnormalities (e.g., intrauterine adhesions, unicornuate\u002F bicornuate\u002F arcuate uterus, large leiomyoma ≥5 cm in diameter; adenomyosis, endometrial polyp, hydrosalpinx).",{"count":195,"type":22},600,[64],"Assisted Reproductive Technologies (ART) aim to increase success rates while minimizing patient risks. For women with high AFC or PCOS, conventional IVF carries a high risk of OHSS (Ho et al., 2019). A modern IVF strategy to prevent this uses a GnRH agonist trigger, requiring a \"freeze-all\" and subsequent FET (Wong et al., 2017). This reduces OHSS risk but can increase time to pregnancy (Vuong et al., 2021) and treatment burden.\n\nIVM is a patient-friendly alternative that eliminates OHSS risk by avoiding high-dose gonadotropins. A 2020 trial by Vuong et al. compared CAPA-IVM-FET to conventional IVF-FET in women with high AFC. IVM yielded a comparable live birth rate (35.2%) versus IVF (43.2%), with a 0% OHSS rate in IVM compared to 0.7% in IVF (Vuong et al., 2020).\n\nThe optimal transfer method (fresh or frozen) in IVM cycles is debated. A 2021 pilot RCT by Vuong et al. found a freeze-only strategy after CAPA-IVM led to a significantly higher live birth rate (60%) than a fresh transfer (20%) (Vuong et al., 2021), but increased time to pregnancy (194 vs. 150 days) (Vuong et al., 2021). A refined CAPA-IVM protocol, which uses no gonadotropins, allowed for fresh embryo transfer in the same cycle, resulting in a numerically higher ongoing pregnancy rate (43.3% vs. 33.3%) than FET (Vuong et al., 2025).\n\nThis raises an important question: how does a simplified IVM strategy with fresh transfer compare to the established \"safety-net\" IVF strategy with FET? These two approaches represent opposing clinical philosophies. No large-scale study has yet compared them in women with PCOS. Therefore, this study is designed to compare the SAIGON protocol (gonadotropin-free CAPA-IVM with fresh ET) against a standard GnRH-antagonist IVF protocol with agonist trigger and subsequent FET.",[199,200,201],"Polycystic Ovary Syndrome (PCOS)","In Vitro Maturation of Oocytes","Fresh Embryo Transfer",[203,204,205,206,37],"in vitro maturation","The SAIGON protocol","fresh embryo transfer","GnRH-Antagonist","2025-09-30",{"date":209,"type":43},"2025-10-01",{"date":211,"type":43},"2025-09-22",{"date":213,"type":22},"2028-01-15",{"name":49,"class":50},{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":222,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":223,"targetDuration":4,"studyType":62,"phases":225,"briefSummary":226,"conditions":227,"keywords":232,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":123},"100544686","letrozole-stimulated-cycle-strategy-versus-artificial-cycle-strategy-letsact-100544686","NCT06372119","Letrozole-stimulated Cycle Strategy Versus Artificial Cycle Strategy (LETSACT)","Letrozole-stimulated Cycle Strategy Versus Artificial Cycle Strategy for Endometrial Preparation in Women With Irregular Menstrual Cycles: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged between 18 - 42.\n* Irregular menstrual cycle (\\\u003C 21 days or \\> 35 days or \\\u003C 8 cycles\u002Fyears).\n* Indicated for endometrial preparation.\n* Transfer of only one blastocyst.\n* Not participating in any other trials.\n\nExclusion Criteria:\n\n* Allergy to letrozole or Ovitrelle or oral estradiol valerate or micronized progesterone\n* Having embryos from either oocyte donation or PGT (pre-implantation genetics testings) cycles.\n* Ovarian cysts that are unrelated to the oocyte pick-up.\n* Confirmed diagnosis with recurrent pregnancy loss (RPL) according to ESHRE guideline 2023, recurrent implantation failure (RIF) according to ESHRE 2023 good practice recommendations.\n* Endometrial abnormalities include endometrial hyperplasia, intrauterine adhesions, endometrial polyp, and chronic endometritis.\n* Uterine abnormalities include leiomyomas L0, L1, or L2 (according to FIGO 2011); adenomyosis (according to MUSA 2022); congenital uterine abnormalities, include didelphus, arcuate, unicornuate, bicornuate, septate (according to ASRM 2021).\n* Untreated hydrosalpinx.",true,{"count":224,"type":22},790,[64],"The goal of this randomized clinical trial is to evaluate the effectiveness of the letrozole-stimulated cycle strategy versus the artificial cycle strategy for endometrial preparation in women with irregular menstrual cycles after one cycle of endometrial preparation. The primary question it aims to answer is:\n\n• Does the letrozole-stimulated cycle strategy for endometrial preparation result in a higher live birth rate compared to the artificial cycle strategy in women with irregular menstrual cycles after one cycle of endometrial preparation?\n\nParticipants will undergo screening before endometrial preparation for frozen embryo transfer, following which they will be randomly assigned to one of two groups: LETS or AC. In the LETS group, investigators will prescribe letrozole 5 milligrams\u002Fday for 5 days to stimulate follicular development and micronized progesterone 800 milligrams\u002Fday for luteal phase support. In contrast, the AC group will receive oral estradiol valerate 6-12 milligrams\u002Fday and micronized progesterone 800 milligrams\u002Fday. Researchers will compare the LETS and AC groups to determine if there are differences in live birth rates.",[228,229,230,231],"Embryo Transfer","Irregular Menstruation","Letrozole","Hormone Replacement Therapy",[233,229,230,231],"Blastocyst Transfer",{"date":235,"type":43},"2025-09-25",{"date":237,"type":43},"2024-04-22",{"date":239,"type":22},"2026-04",{"name":49,"class":50},{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":222,"sex":17,"minAge":18,"maxAge":165,"enrollmentInfo":248,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":250,"conditions":251,"keywords":254,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":257,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":123},"100478488","uterine-microbiome-in-recurrent-pregnancy-loss-100478488","NCT05510622","Uterine Microbiome in Recurrent Pregnancy Loss","Reproductive Tract Microbiome in Women With Recurrent Pregnancy Loss","1. Recurrent pregnancy loss patients\n\n   Inclusion Criteria:\n   * 18-38 years old\n   * Having a regular menstrual cycle, from 25 to 35 days\n   * Having ≥ 2 recurrent pregnancy loss and\n   * Couples with normal karyotype results\n   * Having no condition causing pregnancy loss such as antiphospholipid syndrome, abnormal thyroid function.\n   * Agree to participate in the study\n\n   Exclusion Criteria:\n   * Irregular menstrual cycle\n   * Having uterine abnormalities (e.g., adenomyosis, intrauterine adhesions, unicornuate\u002F bicornuate\u002F arcuate uterus; unremoved hydrosalpinx, endometrial polyp, submucosal fibroid)\n   * Using intrauterine device within the last 3 months\n   * Using antibiotic\u002Fvaginal pessary\u002Fcontraceptive pills within 2 weeks\n   * Having sexual intercourse within 48 hours\n2. Healthy control patients\n\nInclusion Criteria:\n\n* 18-38 years old\n* Having a regular menstrual cycle, from 25 to 35 days\n* No history of pregnancy loss\n* Having 1 or more live birth, with the youngest child ≥ 6 months old\n* Agree to participate in the study\n\nExclusion Criteria:\n\n* Irregular menstrual cycle\n* Having uterine abnormalities (e.g., adenomyosis, intrauterine adhesions, unicornuate\u002F bicornuate\u002F arcuate uterus; unremoved hydrosalpinx, endometrial polyp, submucosal fibroid)\n* Using intrauterine device within the last 3 months\n* Using antibiotic\u002Fvaginal pessary\u002Fcontraceptive pills within 2 weeks\n* Having sexual intercourse within 48 hours",{"count":249,"type":22},100,"The female genital tract microbiome may reflect female reproductive health and may be related to pregnancy outcomes. Disturbances in this microbiome may be associated with adverse reproductive outcomes. The investigators hypothesize that the endometrial and vaginal microbiome composition in women with a history of recurrent pregnancy loss are different, compared with those in normal fertile women.",[252,253],"Recurrent Pregnancy Loss, Not Pregnant","Vaginal Microbiome",[255,256],"Microbiome","Recurrent Pregnancy Loss",{"date":235,"type":43},{"date":259,"type":43},"2022-12-12",{"date":261,"type":22},"2026-05",{"name":49,"class":50},{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":62,"phases":273,"briefSummary":274,"conditions":275,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":51},"100599757","single-step-protocol-and-multi-step-warming-protocol-for-blastocyst-fet-100599757","NCT07088640","Single Step Protocol and Multi-step Warming Protocol for Blastocyst FET","The Live Birth Rate Between Single and Multi-step Warming Protocol Applied in Blastocyst Vitrification: a Randomized Controlled Trial","ONESTEP","Inclusion Criteria:\n\n* Women aged from 18\n* Undergoing no more than 3 previous IVF\u002FICSI cycles\n* Had at least a single good-quality blastocyst frozen.\n* Endometrium preparation using artificial cycle\n* Agree to single blastocyst transfer\n* Not participating in any interventional studies at the same time\n\nExclusion Criteria:\n\n* Embryos from cycles after in-vitro maturation, pre-implantation genetic testing (PGT)\n* Having contraindications for exogenous hormone administration (e.g., breast cancer, thromboembolic disease)\n* Having uterine abnormalities (e.g., adenomyosis, intrauterine adhesions, unicornuate\u002F bicornuate\u002F arcuate uterus; unremoved hydrosalpinx or endometrial polyp)",{"count":272,"type":22},816,[64],"The multi-step thawing protocol with a reduction of non-permeable cryoprotectant concentrations to reduce osmotic shock caused by the rapid influx of water. Recent studies have shown that a simplified warming protocol by only a thawing solution gave a comparable survival rate but increased pregnancy rate, reduced patients' waiting time, and decreased the workload of embryologists.",[68,30,276],"Embryo Thawing Protocol","2025-09-10",{"date":279,"type":43},"2025-09-12",{"date":281,"type":43},"2025-08-13",{"date":283,"type":22},"2027-03-01",{"name":49,"class":50},{"id":286,"slug":287,"hasResults":11,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":291,"eligibilityCriteria":292,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":62,"phases":295,"briefSummary":296,"conditions":297,"keywords":300,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":51},"100551712","cerclage-with-progesterone-versus-progesterone-only-in-singleton-pregnancies-100551712","NCT06463652","Cerclage With Progesterone Versus Progesterone Only in Singleton Pregnancies","Cervical Cerclage With Vaginal Progesterone Versus Vaginal Progesterone Only for Preterm Birth Prevention in Women With a Singleton Pregnancy and a Short Cervical Length: a Randomized Clinical Trial","RESILIENT","Inclusion Criteria:\n\n* Maternal age ≥18 years\n* Singleton pregnancy\n* Cervical length ≤ 25 mm, measured by TVS at the second-trimester ultrasonography (16 0\u002F7 - 24 0\u002F7 weeks of gestation)\n* Not participating in any other study which has intervention on maternity or fetus\n* Provision of written informed consent as shown by a signature on the participant consent form.\n\nExclusion Criteria:\n\n* Cervical dilation with visible amniotic membranes or amniotic membranes prolapsed into the vagina\n* Major congenital abnormalities of the fetus\n* Intrauterine fetal demise\n* Presence of severe vaginal discharge\\*\n* Presence of vaginitis or cervicitis\\*\n* Presence of vaginal bleeding\\*\n* Placenta previa or vasa previa\n* Preterm premature rupture of membranes\n* Preterm labor without ruptured membrane at the time of screening\n* Suspected chorioamnionitis\n* Unable to undergo cerclage\n* Cerclage in place\n* Allergy to progesterone\n\n(\\*Women with acute cervicitis, vaginitis or severe vaginal discharge are eligible once they have been treated and if they have a CL ≤25 mm between 16 0\u002F7 - 24 0\u002F7 weeks of gestation.)",{"count":294,"type":22},328,[64],"This study compares the effectiveness of cervical cerclage with vaginal progesterone to vaginal progesterone only for the prevention of preterm birth in women with a singleton pregnancy and a short cervical length. Participants will be randomly assigned in a 1:1 ratio to receive cerclage plus progesterone or progesterone only.",[298,299],"Preterm Birth","Short Cervix",[301,302,303,304],"Cerclage","Progesterone","Singleton","Preterm birth",{"date":306,"type":43},"2025-09-16",{"date":308,"type":43},"2024-06-26",{"date":310,"type":22},"2026-10",{"name":49,"class":50},{"id":313,"slug":314,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":222,"sex":320,"minAge":321,"maxAge":322,"enrollmentInfo":323,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":325,"conditions":326,"keywords":329,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":336,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":51},"100477884","development-of-ivficsi-children-born-from-different-endometrial-preparation-protocols-100477884","NCT05502770","Development of IVF\u002FICSI Children Born From Different Endometrial Preparation Protocols","Development of IVF\u002FICSI Children Born From Frozen Embryo Transfer Cycles With Different Endometrial Preparation Protocols: Follow-up of a Randomized Controlled Trial","MONARTBABIES","Inclusion Criteria:\n\n* All live IVF\u002FICSI babies born from frozen embryo transfer following the natural cycle, modified natural cycle, and artificial cycle from MONART study\n* Parents agree to participate in the study.\n\nExclusion Criteria:\n\n* Babies died under or at 24 months","ALL","6 Months","18 Months",{"count":324,"type":22},700,"The efficacy and safety of endometrial preparation regimens remain controversial. In the most recent meta-analysis, using natural and modified natural cycle protocol to prepare the endometrium in frozen embryo transfer resulted in higher live birth rates. In addition, the natural cycle reduces the risk of gestational hypertension, postpartum haemorrhage, and extremely preterm delivery compared with regimens using exogenous hormones.\n\nBecause there are many physiological and endocrinal differences in the frozen embryo transfer cycle with different endometrial preparation protocols, the development of children born from these regimens has received much attention. For example, there is a complete absence of the corpus luteum during the cycle of exogenous hormone administration. Or in the modified natural cycle, the pharmacokinetics is not entirely the same as the natural physiology when using an additional ovulatory injection with hCG. To date, there have been no longitudinal follow-up studies that evaluated and compared the long-term development of IVF\u002FICSI children born from frozen embryo transfer with different endometrial preparation protocols.\n\nThus, the investigators conduct a follow-up of our RCT to investigate the IVF\u002FICSI children born from frozen embryo transfer with different endometrial preparation protocols to give strong evidence about the safety of the three most common endometrial preparation protocols in women undergoing frozen embryo transfer.",[327,328],"Child Development","Endometrial Preparation",[330,331,332,333,334,335],"Child development","Endometrial preparation","IVF\u002FICSI","Natural cycle","Modified natural cycle","Artificial cycle",{"date":306,"type":43},{"date":338,"type":43},"2022-08-12",{"date":340,"type":22},"2025-12",{"name":49,"class":50},{"id":343,"slug":344,"hasResults":11,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":350,"enrollmentInfo":351,"targetDuration":4,"studyType":62,"phases":352,"briefSummary":353,"conditions":354,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":51},"100587930","le--cc-vs-le-for-ovulation-induction-100587930","NCT06934785","LE + CC vs. LE for Ovulation Induction","The Combination of Letrozole (LE) and Clomiphene Citrate (CC) or LE Alone for Ovulation Induction in Women With WHO Group II\u002FIV Ovulatory Disorders: A Randomized Controlled Trial","COLA","Inclusion Criteria:\n\n* Women 18-40 years of age\n* Having WHO II\u002FIV ovulatory disorders (length of cycle \\\u003C 21 or \\> 35 days or having \\\u003C 8 cycles per year)\n* Progressive motility (PR) ≥ 32%, sperm concentration ≥ 5 million\u002Fml, total progressive motility sperm count \\> 5 million (World Health Organization, 2021)\n* Written informed consent.\n* Not participating in other studies.\n\nExclusion Criteria:\n\n* Untreated thyroid disease; Thyroid disease is suspected if patients have one of these (Bednarczuk et al., 2021); TSH ≥4 mIU\u002FL or TSH ≥2.5mIU\u002FL and TPOAb (+) or TSH \\\u003C0.1mIU\u002FL\n* Untreated hyper-prolactinemia; Hyperprolactinemia is suspected if patients have prolactinemia concentration \\>50 ng\u002FmL (The sample is collected after an overnight fast, at least 2 hours after waking up, ensuring that venipuncture does not cause excessive stress.)\n* Allergy or having contraindications to LE or CC;\n* Unilateral or Bilateral fallopian tube blockage (HSG, HyFoSy or surgery confirmation)\n* Untreated endometrial abnormalities include endometrial hyperplasia, intrauterine adhesions, endometrial polyp, or chronic endometritis.\n* Uterine abnormalities include leiomyomas L0, L1, or L2; severe adenomyosis; congenital uterine abnormalities, include didelphus, arcuate, unicornuate, bicornuate, septate.","40 Years",{"count":195,"type":22},[64],"This randomized controlled trial (RCT) aims to evaluate whether, in infertile women with WHO II\u002FIV ovulatory disorders, a combination of letrozole (LE) and clomiphene citrate (CC) compared to LE alone, result in higher live birth rates.\n\nThe study is designed as an open-label, multicenter RCT across six fertility clinics in Vietnam. Participants will be randomized into two groups: (1) LE + CC , (2) LE alone. The primary outcome measure is the live birth rate after one treatment cycle. Based on prior data, the live birth rate for IUI in letrozole cycles is estimated at 12%. To detect a 10% increase in live birth rates with CC, 436 couples are needed (α = 0.05, power = 80%). Additionally, the live birth rate after IUI with LE-induced ovulation is approximately 18.7% (Diamond et al., 2015). To detect a 10% increase with CC, 560 couples are required (α = 0.05, power = 80%). Considering a 5% loss to follow-up and protocol deviations, the study plans to recruit 600 participants (150 per arm).",[230,355,356,357],"Clomiphene Citrate","Ovulation Disorder","Ovulation Induction","2025-09-04",{"date":360,"type":43},"2025-09-11",{"date":362,"type":43},"2025-04-28",{"date":364,"type":22},"2027-06-30",{"name":49,"class":50},{"id":367,"slug":368,"hasResults":11,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":372,"eligibilityCriteria":373,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":165,"enrollmentInfo":374,"targetDuration":4,"studyType":62,"phases":376,"briefSummary":377,"conditions":378,"keywords":380,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":51},"100575001","effect-of-super-gdf9-on-capa-ivm-of-cocs-from-small-antral-follicles-100575001","NCT06766604","Effect of Super-GDF9 on CAPA-IVM of COCs From Small Antral Follicles","Exploratory In-vitro Study Evaluating the Addition of Super-GDF9 During Capacitation-in-vitro Maturation (CAPA-IVM) of Donated Human Cumulus-oocyte Complexes (COCs) Derived From Small Antral Follicles","sGDF-9","Inclusion Criteria:\n\n1. Women between the ages of 18 and 38 years (both inclusive)\n2. BMI ≤ 32 kg\u002Fm2\n3. PCOS women according to the Rotterdam criteria (2003)\n4. Indicating CAPA-IVM treatment.\n5. Serum AMH ≥ 4 ng\u002FmL (28.57 pmol\u002FL) at screening and having at least 24 antral follicles in two ovaries by transvaginal ultrasound at the time of CAPA-IVM indication\n6. Willing to donate COCs for research purposes\n7. Agreeing for frozen embryo\n8. Signed informed consent before any study-related procedures\n\nExclusion Criteria:\n\n1. Known endometrioma or grade 3-4 endometriosis according to ASRM classification\n2. Uterine abnormalities\n3. Couples with severe male factor (sperm concentration \\\u003C5 million\u002Fml, motility \\\u003C 10%), surgical sperm retrieval.\n4. Previous history of unexplained immature oocytes after IVF treatment\n5. Cycles using donor oocytes",{"count":375,"type":22},9,[64],"CAPA-IVM (In Vitro Maturation) technology is an assisted reproductive method offering significant benefits in terms of safety and treatment costs, particularly for high-risk patients. These include individuals with ovarian hyperstimulation syndrome (OHSS), venous thrombosis, ovarian torsion, or polycystic ovary syndrome (PCOS). However, while the live birth rate in the CAPA-IVM group (35.2%) is comparable to conventional IVF (43.2%), the number of good-quality embryos and cumulative clinical pregnancy rates remain lower. Improving the CAPA-IVM culture process, particularly through the addition of growth factors found in follicular fluid, has shown promise in enhancing oocyte quality.\n\nGrowth differentiation factor 9 (GDF9) and Bone morphogenetic protein 15 (BMP15) play critical roles in follicular development, with their heterodimer structure demonstrating the most positive effects on cumulus-oocyte complexes (COCs). Recent studies have identified a potent variant, super GDF9, which is \\>1000 times more effective than GDF9 and surpasses cumulin, a heterodimeric growth factor. Super GDF9 enhances cumulus cell expansion and oocyte developmental competence, closely mimicking in vivo maturation.\n\nThis study investigates the impact of supplementing super GDF9 during CAPA-IVM culture, aiming to improve outcomes of cumulus-oocyte complexes (COCs) from small follicles and ultimately enhance treatment success.",[379],"In Vitro Fertilization",[176,381,382,383,384],"super-GDF9","Culture","OSFs","PCOS","2025-07-09",{"date":387,"type":43},"2025-07-10",{"date":389,"type":43},"2025-01-10",{"date":391,"type":22},"2026-04-30",{"name":49,"class":50},{"id":394,"slug":395,"hasResults":11,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":4,"eligibilityCriteria":399,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":400,"enrollmentInfo":401,"targetDuration":4,"studyType":62,"phases":403,"briefSummary":404,"conditions":405,"keywords":407,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":51},"100573330","capa---ivm-in-ovulatory-infertile-women-100573330","NCT06744881","CAPA - IVM in Ovulatory Infertile Women","The Effectiveness and Safety of CAPA - IVM in Ovulatory Infertile Women: a Pilot Study","Inclusion Criteria:\n\n* Ageing from 18 to 37.\n* Women without PCOS:\n\n  * Having regular periods: \\>24 days and \\\u003C35 days.\n  * And not having clinical hyperandrogenism or biochemical hyperandrogenism.\n  * And not presenting with peripheral distribution of polycystic ovaries on ultrasound.\n  * Antral follicle count 15 ≤AFC ≤ 24 and Anti-Mullerian Hormone 2,1 ≤ AMH ≤ 5 ng\u002FmL)\n* Having indication for ART\n* First ART cycle.\n* No ovarian stimulation 3 months prior to study entry\n* Agree to have all embryos frozen on day 3 or day 5.\n* Agree to transfer no more than 02 cleavage-stage embryos or 01 blastocyst-stage embryo in a subsequent embryo transfer.\n* Agree to participate in the study (Agree to undergo CAPA-IVM).\n\nExclusion Criteria:\n\n* Donor oocyte cycles.\n* Uterine abnormalities (adenomyosis, leiomyoma (≥5 cm), bicornuate uterus, intrauterine adhesion).\n* Prior ovarian surgery.\n* Surgically extracted sperm (by PESA, TESE or micro TESE).","37 Years",{"count":402,"type":22},20,[64],"In vitro maturation (IVM) is an assisted reproductive technology (ART) using minimal or no ovarian stimulation. In IVM, immature oocytes at the germinal vesical (GV) or metaphase I (MI) stage retrieved from small antral follicles are cultured to reach metaphase II (MII) (ASRM, 2021).\n\nSince the first successful IVM baby was reported, subsequent studies have been mostly focused on patients with polycystic ovary syndrome (PCOS) to reduce the risks associated with ovarian stimulation such as ovarian hyperstimulation syndrome (OHSS), thromboembolic complications and ovarian torsion (Cha et al., 1991; Chian et al., 2000). Numerous IVM protocols have been applied with or without FSH or hCG priming and using one step or two steps culture system to gain the optimum oocyte maturation rate, blastulation rate and live birth rate (Sanchez et al., 2019; De Vos et al., 2021).\n\nA randomized controlled trial (RCT) conducted on women with high antral follicle count, including women with PCOS, indicated that CAPA-IVM was non-inferior to conventional IVF (Vuong et al., 2020). Studies also showed that the mental and motor development of children born after IVM was similar to that of those born after IVF and naturally conceived (Nguyen et al., 2022; Vuong et al., 2022). Additionally, IVM is considered an effective treatment for women with gonadotropin resistant ovary syndrome to have children with their own oocytes (Le et al., 2021). IVM is also a viable option for fertility preservation for women with cancer in need of urgent treatment and contraindicated to hormonal stimulation (Grynberg et al., 2022).\n\nThere is little evidence on the effectiveness of IVM on women without PCOS. Junk et al have compared the effectiveness of IVM between women with polycystic ovaries (PCO) and polycystic ovary syndrome (Junk and Yeap, 2012). Women with PCO had significantly lower oocytes collected than those with PCOS (p\\\u003C0,001), maturation rate, blastocyst development rate, and clinical pregnancy rate were comparable between two groups (Junk and Yeap, 2012). Another study indicated the maturation rate after standard IVM of ovarian tissue-derived oocytes collected from cancer patients was 8-67% (Segers et al., 2020). A study conducted by Kirillova on ovarian cancer patients with normal to high ovarian reserve showed that CAPA-IVM resulted in a higher maturation rate in ovarian tissue oocytes compared to standard IVM (56% vs 36%, p=0.0045) (Kirillova et al., 2021).\n\nRecently, IVF\u002FICSI has been indicated in almost all infertility patients without PCOS. A randomized controlled trial on non-PCOS women with high antral follicle counts revealed no significant differences between IVM and conventional IVF regarding the ongoing pregnancy rate, live birth rate and the incidence of pregnancy and perinatal complications (Vuong et al., 2020). IVM offers numerous advantages due to the concept of using mild or no stimulation. The risk of ovarian hyperstimulation syndrome is largely eliminated, the cost of treatment is notably reduced. IVM is also more convenient as it requires fewer patient visits, ultrasounds and blood tests (Ho and Vuong, 2023).\n\nTherefore, this pilot study is to evaluate the effectiveness and safety of CAPA-IVM in ovulatory infertile women and evaluate its success rate in relation to their ovarian reserve.",[406],"Ovulatory Infertile Women",[176],"2024-12-23",{"date":410,"type":43},"2024-12-27",{"date":412,"type":22},"2024-12-20",{"date":414,"type":22},"2025-12-30",{"name":49,"class":50},{"id":417,"slug":418,"hasResults":11,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":422,"eligibilityCriteria":423,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":424,"targetDuration":4,"studyType":62,"phases":426,"briefSummary":427,"conditions":428,"keywords":430,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":4},"100559421","lipiodol-prior-to-fet-life-100559421","NCT06563908","Lipiodol Prior to FET (LIFE)","Lipiodol® For Enhancing Live Birth Rates In Infertile Couples Undergoing In Vitro Fertilization\u002F Intracytoplasmic Sperm Injection A Randomized Controlled Trial","LIFE","Inclusion Criteria:\n\n* Women undergoing IVF\u002FICSI\n* Having indications for freeze-all (day-3 or day-5)\n* Agree to have ≤ 2 frozen embryos transferred\n* TSH \\\u003C 2.5 mIU\u002FmL\n* Permanent resident in Viet Nam\n* Agree to participate in the study by signing the inform consent\n\nExclusion Criteria:\n\n* Iodine allergy\n* History of salpingectomy or tubal ligation\n* History of using Lipiodol® within 6 months prior, starting from the screening time\n* At high risk of having Fallopian tube disorders (history of Chlamydia infection, history of pelvic inflammatory diseases, current endometriosis)\n* Having evidence of Fallopian tube disorders on Hysterosalpingo - Foam Sonography (HyFoSy), hysterosalpingography (HSG), ultrasonography or laparoscopy\n* Having untreated intrauterine lesions such as endometrial polyps, submucosal fibroids, etc which affect the outcome of IVF treatment\n* Have a history of thyroid disease or being treated for thyroid disease\n* Undergoing curettage within 30 days before performing HSG technique\n* Patients having embryos from oocyte donation or in vitro maturation (IVM) cycles\n* Unable or unwilling to attend Lipiodol® procedure\n* Participating in another interventional study at the same time",{"count":425,"type":22},784,[64],"Lipiodol® flushing is an effective fertility treatment for women with unexplained infertility. It is speculated that the treatment effect could work through a direct effect of Lipiodol® on the endometrium. Given this direct effect on the endometrium, it is further hypothesized that Lipiodol® uterine treatment prior to In Vitro Fertilization (IVF)\u002F Intracytoplasmic Sperm Injection (ICSI) may also improve pregnancy rates. However, the effectiveness of Lipiodol® as an adjunct to IVF\u002FICSI treatment has not previously been examined in a well-powered and properly conducted randomised clinical trial.",[68,69,429],"Hysterosalpingography",[431,429],"Lipiodol","2024-08-18",{"date":434,"type":43},"2024-08-21",{"date":436,"type":22},"2024-08-10",{"date":438,"type":22},"2026-12",{"name":49,"class":50},""]